Design and analysis of rhesus cytomegalovirus IL-10 mutants as a model for novel vaccines against human cytomegalovirus

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Logsdon, Naomi J ^a   Eberhardt, Meghan K ^b   Allen, Christopher E ^a   Barry, Peter A ^b   Walter, Mark R ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 10 RECEPTOR 1; INTERLEUKIN 12; RHESUS CYTOMEGALOVIRUS INTERLEUKIN 10; UNCLASSIFIED DRUG; CYTOMEGALOVIRUS VACCINE; INTERLEUKIN 10 RECEPTOR ALPHA; MUTANT PROTEIN; NEUTRALIZING ANTIBODY;

ADAPTIVE IMMUNITY; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; COMPLEX FORMATION; CONTROLLED STUDY; CROSS REACTION; CRYSTAL STRUCTURE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOMEGALOVIRUS INFECTION; DNA IMMUNIZATION; DRUG DESIGN; DRUG SCREENING; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; HYDROGEN BOND; IMMUNE RESPONSE; IMMUNOSTIMULATION; INNATE IMMUNITY; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; RECEPTOR BINDING; RHESUS MONKEY; VIRUS NEUTRALIZATION; WILD TYPE; ANIMAL; BIOLOGICAL MODEL; BLOOD; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; CYTOLOGY; CYTOMEGALOVIRUS; GENETICS; IMMUNIZATION; IMMUNOLOGY; ISOLATION AND PURIFICATION; MACACA MULATTA; MOLECULAR GENETICS; MONONUCLEAR CELL; POINT MUTATION; PROTEIN BINDING; PROTEIN QUATERNARY STRUCTURE; SURFACE PLASMON RESONANCE;

CERCOPITHECINE HERPESVIRUS 8; HUMAN HERPESVIRUS 5; MACACA MULATTA;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, NEUTRALIZING; CELL PROLIFERATION; CROSS REACTIONS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS VACCINES; DRUG DESIGN; HUMANS; IMMUNIZATION; INTERLEUKIN-10; INTERLEUKIN-10 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-12; LEUKOCYTES, MONONUCLEAR; MACACA MULATTA; MODELS, IMMUNOLOGICAL; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTANT PROTEINS; POINT MUTATION; PROTEIN BINDING; PROTEIN STRUCTURE, QUATERNARY; SURFACE PLASMON RESONANCE;

EID: 81455140761     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028127     Document Type: Article

References (64)

1. Staras SA, Dollard SC, Radford KW, Flanders WD, Pass RF, et al. (2006) Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis 43: 1143-1151.
2. Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, et al. (2005) Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 202: 673-685.
3. Macagno A, Bernasconi NL, Vanzetta F, Dander E, Sarasini A, et al. (2010) Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol 84: 1005-1013.
4. Cui X, Meza BP, Adler SP, McVoy MA, (2008) Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine 26: 5760-5766.
5. Crough T, Khanna R, (2009) Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev 22: 76-98, Table of Contents.
6. Ross SA, Arora N, Novak Z, Fowler KB, Britt WJ,et al. Cytomegalovirus reinfections in healthy seroimmune women. J Infect Dis 201: 386-389.
7. Kedhar SR, Jabs DA, (2007) Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Herpes 14: 66-71.
8. Hanshaw JB, (1971) Congenital cytomegalovirus infection: a fifteen year perspective. J Infect Dis 123: 555-561.
9. Plotkin SA, (1999) Cytomegalovirus vaccine. Am Heart J 138: S484-487.
10. Weller TH, (1971) The cytomegaloviruses: ubiquitous agents with protean clinical manifestations. I. N Engl J Med 285: 203-214.
11. Yow MD, (1989) Congenital cytomegalovirus disease: a NOW problem. J Infect Dis 159: 163-167.
12. Pass RF, Zhang C, Evans A, Simpson T, Andrews W, et al. (2009) Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 360: 1191-1199.
13. Griffiths PD, Stanton A, McCarrell E, Smith C, Osman M, et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 377: 1256-1263.
14. Mocarski ES Jr, (2002) Immunomodulation by cytomegaloviruses: manipulative strategies beyond evasion. Trends Microbiol 10: 332-339.
15. Chang WL, Barry PA, Attenuation of innate immunity by cytomegalovirus IL-10 establishes a long-term deficit of adaptive antiviral immunity. Proc Natl Acad Sci U S A 107: 22647-22652.
16. Chang WL, Baumgarth N, Yu D, Barry PA, (2004) Human cytomegalovirus-encoded interleukin-10 homolog inhibits maturation of dendritic cells and alters their functionality. J Virol 78: 8720-8731.
17. Chang WL, Baumgarth N, Eberhardt MK, Lee CY, Baron CA, et al. (2007) Exposure of myeloid dendritic cells to exogenous or endogenous IL-10 during maturation determines their longevity. J Immunol 178: 7794-7804.
18. Spencer JV, Lockridge KM, Barry PA, Lin G, Tsang M, et al. (2002) Potent immunosuppressive activities of cytomegalovirus-encoded interleukin-10. J Virol 76: 1285-1292.
19. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A, (2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19: 683-765.
20. Kotenko SV, Saccani S, Izotova LS, Mirochnitchenko OV, Pestka S, (2000) Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). Proc Natl Acad Sci U S A 97: 1695-1700.
21. Jones BC, Logsdon NJ, Josephson K, Cook J, Barry PA, et al. (2002) Crystal structure of human cytomegalovirus IL-10 bound to soluble human IL-10R1. Proc Natl Acad Sci U S A 99: 9404-9409.
22. Yoon SI, Jones BC, Logsdon NJ, Walter MR, (2005) Same structure, different function crystal structure of the Epstein-Barr virus IL-10 bound to the soluble IL-10R1 chain. Structure 13: 551-564.
23. Yoon SI, Logsdon NJ, Sheikh F, Donnelly RP, Walter MR, (2006) Conformational changes mediate interleukin-10 receptor 2 (IL-10R2) binding to IL-10 and assembly of the signaling complex. J Biol Chem 281: 35088-35096.
24. Yamamoto-Tabata T, McDonagh S, Chang HT, Fisher S, Pereira L, (2004) Human cytomegalovirus interleukin-10 downregulates metalloproteinase activity and impairs endothelial cell migration and placental cytotrophoblast invasiveness in vitro. J Virol 78: 2831-2840.
25. Garrigue I, Corte MF, Magnin N, Couzi L, Capdepont S, et al. (2007) Variability of UL18, UL40, UL111a and US3 immunomodulatory genes among human cytomegalovirus clinical isolates from renal transplant recipients. J Clin Virol 40: 120-128.
26. Yue Y, Barry PA, (2008) Rhesus cytomegalovirus a nonhuman primate model for the study of human cytomegalovirus. Adv Virus Res 72: 207-226.
27. Josephson K, Logsdon NJ, Walter MR, (2001) Crystal structure of the IL-10/IL-10R1 complex reveals a shared receptor binding site. Immunity 15: 35-46.
28. Walter MR, Nagabhushan TL, (1995) Crystal structure of interleukin 10 reveals an interferon gamma-like fold. Biochemistry 34: 12118-12125.
29. Windsor WT, Syto R, Tsarbopoulos A, Zhang R, Durkin J, et al. (1993) Disulfide bond assignments and secondary structure analysis of human and murine interleukin 10. Biochemistry 32: 8807-8815.
30. Zdanov A, Schalk-Hihi C, Gustchina A, Tsang M, Weatherbee J, et al. (1995) Crystal structure of interleukin-10 reveals the functional dimer with an unexpected topological similarity to interferon gamma. Structure 3: 591-601.
31. Liu Y, de Waal Malefyt R, Briere F, Parham C, Bridon JM, et al. (1997) The EBV IL-10 homologue is a selective agonist with impaired binding to the IL-10 receptor. J Immunol 158: 604-613.
32. Humphreys IR, de Trez C, Kinkade A, Benedict CA, Croft M, et al. (2007) Cytomegalovirus exploits IL-10-mediated immune regulation in the salivary glands. J Exp Med 204: 1217-1225.
33. Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, et al. (2006) Interleukin-10 determines viral clearance or persistence in vivo. Nat Med 12: 1301-1309.
34. Ejrnaes M, Filippi CM, Martinic MM, Ling EM, Togher LM, et al. (2006) Resolution of a chronic viral infection after interleukin-10 receptor blockade. J Exp Med 203: 2461-2472.
35. Perez AB, Garcia G, Sierra B, Alvarez M, Vazquez S, et al. (2004) IL-10 levels in Dengue patients: some findings from the exceptional epidemiological conditions in Cuba. J Med Virol 73: 230-234.
36. Ubol S, Phuklia W, Kalayanarooj S, Modhiran N, Mechanisms of immune evasion induced by a complex of dengue virus and preexisting enhancing antibodies. J Infect Dis 201: 923-935.
37. Alter G, Kavanagh D, Rihn S, Luteijn R, Brooks D, et al. IL-10 induces aberrant deletion of dendritic cells by natural killer cells in the context of HIV infection. J Clin Invest 120: 1905-1913.
38. Song W, Li Y, Wilson CM, Tang J, Identification of Three Immunologic Correlates for HIV Type 1 Pathogenesis in Youth. AIDS Res Hum Retroviruses 27: 639-646.
39. Bolpetti A, Silva JS, Villa LL, Lepique AP, Interleukin-10 production by tumor infiltrating macrophages plays a role in Human Papillomavirus 16 tumor growth. BMC Immunol 11: 27.
40. Kaplan DE, Ikeda F, Li Y, Nakamoto N, Ganesan S, et al. (2008) Peripheral virus-specific T-cell interleukin-10 responses develop early in acute hepatitis C infection and become dominant in chronic hepatitis. J Hepatol 48: 903-913.
41. Li J, Wu W, Peng G, Chen F, Bai M, et al. HBcAg induces interleukin-10 production, inhibiting HBcAg-specific Th17 responses in chronic hepatitis B patients. Immunol Cell Biol 88: 834-841.
42. Barboza L, Salmen S, Peterson DL, Montes H, Colmenares M, et al. (2009) Altered T cell costimulation during chronic hepatitis B infection. Cell Immunol 257: 61-68.
43. de la Barrera S, Aleman M, Musella R, Schierloh P, Pasquinelli V, et al. (2004) IL-10 down-regulates costimulatory molecules on Mycobacterium tuberculosis-pulsed macrophages and impairs the lytic activity of CD4 and CD8 CTL in tuberculosis patients. Clin Exp Immunol 138: 128-138.
44. Marks E, Tam MA, Lycke NY, The female lower genital tract is a privileged compartment with IL-10 producing dendritic cells and poor Th1 immunity following Chlamydia trachomatis infection. PLoS Pathog 6: e1001179.
45. Biswas PS, Pedicord V, Ploss A, Menet E, Leiner I, et al. (2007) Pathogen-specific CD8 T cell responses are directly inhibited by IL-10. J Immunol 179: 4520-4528.
46. Silverman JM, Clos J, Horakova E, Wang AY, Wiesgigl M, et al. Leishmania exosomes modulate innate and adaptive immune responses through effects on monocytes and dendritic cells. J Immunol 185: 5011-5022.
47. Peters N, Sacks D, (2006) Immune privilege in sites of chronic infection: Leishmania and regulatory T cells. Immunol Rev 213: 159-179.
48. Bueno LL, Morais CG, Araujo FF, Gomes JA, Correa-Oliveira R, et al. (9623) Plasmodium vivax: induction of CD4+CD25+FoxP3+ regulatory T cells during infection are directly associated with level of circulating parasites. PLoS One 5: e9623.
49. Moreira AP, Dias-Melicio LA, Soares AM, Interleukin-10 but not Transforming Growth Factor beta inhibits murine activated macrophages Paracoccidioides brasiliensis killing: effect on H2O2 and NO production. Cell Immunol 263: 196-203.
50. Wilson EB, Brooks DG, The role of IL-10 in regulating immunity to persistent viral infections. Curr Top Microbiol Immunol 350: 39-65.
51. Lockridge KM, Zhou SS, Kravitz RH, Johnson JL, Sawai ET, et al. (2000) Primate cytomegaloviruses encode and express an IL-10-like protein. Virology 268: 272-280.
52. Cunningham C, Gatherer D, Hilfrich B, Baluchova K, Dargan DJ, et al. Sequences of complete human cytomegalovirus genomes from infected cell cultures and clinical specimens. J Gen Virol 91: 605-615.
53. Redpath S, Angulo A, Gascoigne NR, Ghazal P, (1999) Murine cytomegalovirus infection down-regulates MHC class II expression on macrophages by induction of IL-10. J Immunol 162: 6701-6707.
54. Jones M, Ladell K, Wynn KK, Stacey MA, Quigley MF, et al. IL-10 restricts memory T cell inflation during cytomegalovirus infection. J Immunol 185: 3583-3592.
55. Campbell AE, Cavanaugh VJ, Slater JS, (2008) The salivary glands as a privileged site of cytomegalovirus immune evasion and persistence. Med Microbiol Immunol 197: 205-213.
56. Jones M, Ladell K, Wynn KK, Stacey MA, Quigley MF, et al. (2010) IL-10 restricts memory T cell inflation during cytomegalovirus infection. J Immunol 185: 3583-3592.
57. Ejrnaes M, von Herrath MG, (2007) Cure of chronic viral infection by neutralizing antibody treatment. Autoimmun Rev 6: 267-271.
58. Yoon SI, Jones BC, Logsdon NJ, Harris BD, Deshpande A, et al. Structure and mechanism of receptor sharing by the IL-10R2 common chain. Structure 18: 638-648.
59. Josephson K, Jones BC, Walter LJ, DiGiacomo R, Indelicato SR, et al. (2002) Non-competitive Antibody Neutralization of IL-10 Revealed by Protein Engineering and X-ray crystallography. Structure 10: 981-987.
60. DeLano WL, (2002) The PyMOL Molecular Graphics System DeLano Scientific, San Carlos, CA, USA. Pymol website. Available: http://www.pymol.org. Accessed 2011 Nov 2.
61. Josephson K, McPherson DT, Walter MR, (2001) Purification, crystallization and preliminary X-ray diffraction of a complex between IL-10 and soluble IL-10R1. Acta Crystallogr D Biol Crystallogr 57: 1908-1911.
62. Loomis-Huff JE, Eberle R, Lockridge KM, Rhodes G, Barry PA, (2001) Immunogenicity of a DNA vaccine against herpes B virus in mice and rhesus macaques. Vaccine 19: 4865-4873.
63. Abel K, Strelow L, Yue Y, Eberhardt MK, Schmidt KA, et al. (2008) A heterologous DNA prime/protein boost immunization strategy for rhesus cytomegalovirus. Vaccine 26: 6013-6025.
64. Yue Y, Zhou SS, Barry PA, (2003) Antibody responses to rhesus cytomegalovirus glycoprotein B in naturally infected rhesus macaques. J Gen Virol 84: 3371-3379.